|
|
|
|
|
|
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (67.1%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (10%);
- other (22.9%).
Net sales break down geographically as follows: the United States (43.1%), Europe-Middle East-Africa (27.5%), Japan (10.8%) and other (18.6%).
| |
| Surperformance© rating of Merck & Co., Inc. | |
|
|
Overall rating |
In sector |
In country |
| Trading Rating |
|
|
|
| Investor Rating |
|
|
|
| Growth (Revenue) |
|
|
|
| Valuation |
|
|
|
| Finances |
|
|
|
| Profitability |
|
|
|
| Earnings quality |
|
|
|
| Business Predictability |
|
|
|
| PER |
|
|
|
| Potential |
|
|
|
| Yield |
|
|
|
| Consensus |
|
|
|
| 7 days EPS revision |
|
|
|
| 4 months EPS revision |
|
|
|
| 1 year EPS revision |
|
|
|
| 4 months Revenue revision |
|
|
|
| 1 year Revenue revision |
|
|
|
| |
| |
|
|
Data source : © 2013 Thomson Reuters |
|
Ratings : © 2013 Surperformance |
|
|
|
|
|
| - Capital World |
6,40% |
| - BlackRock |
5,75% |
|
|
|
|
- General Secretary : Celia A. Colbert |
- Chief Financial Officer : Peter N. Kellogg |
- Chairman and Chief Executive Officer : Kenneth C. Frazier |
|
|
| Company contact information |
|
One Merk Drive PO Box 100 NJ 08889-0100 Whitehouse Station, New Jersey USA
Phone : +1 908 423 1000 Fax : +1 908 735 1253 Internet : http://www.merck.com
|
|
|
|
- NYSE Euronext Paris - Eurolist hors zone Euro - CAC International 25 / DJIA, SP100, SP500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50 |
|
|
|
|
| - ISIN Code : |
US58933Y1055 |
| - Bloomberg Code : |
|
| - Reuters Code : |
MRK.PA |
| - Datastream Code : |
F:MERC |
|
Financial data source : © 2013 Cofisem |
|
|